Cargando…

Validation of in silico biomarkers for drug screening through ordinal logistic regression

Since the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiation, many studies have suggested various in silico features based on ionic charges, action potentials (AP), or intracellular calcium (Ca) to assess proarrhythmic risk. These in silico features are computed through electrophysiologica...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeong, Da Un, Danadibrata, Rakha Zharfarizqi, Marcellinus, Aroli, Lim, Ki Moo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583152/
https://www.ncbi.nlm.nih.gov/pubmed/36277213
http://dx.doi.org/10.3389/fphys.2022.1009647
_version_ 1784813006646935552
author Jeong, Da Un
Danadibrata, Rakha Zharfarizqi
Marcellinus, Aroli
Lim, Ki Moo
author_facet Jeong, Da Un
Danadibrata, Rakha Zharfarizqi
Marcellinus, Aroli
Lim, Ki Moo
author_sort Jeong, Da Un
collection PubMed
description Since the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiation, many studies have suggested various in silico features based on ionic charges, action potentials (AP), or intracellular calcium (Ca) to assess proarrhythmic risk. These in silico features are computed through electrophysiological simulations using in vitro experimental datasets as input, therefore changing with the quality of in vitro experimental data; however, research to validate the robustness of in silico features for proarrhythmic risk assessment of drugs depending on in vitro datasets has not been conducted. This study aims to verify the availability of in silico features commonly used in assessing the cardiac toxicity of drugs through an ordinal logistic regression model and three in vitro datasets measured under different experimental environments and with different purposes. We performed in silico drug simulations using the Tomek-Ohara Rudy (ToR-ORD) ventricular myocyte model and computed 12 in silico features comprising six AP features, four Ca features, and two ion charge features, which reflected the effect and characteristics of each in vitro data for CiPA 28 drugs. We then compared the classific performances of ordinal logistic regressions according to these 12 in silico features and used in vitro datasets to validate which in silico feature is the best for assessing the proarrhythmic risk of drugs at high, intermediate, and low levels. All 12 in silico features helped determine high-risky torsadogenic drugs, regardless of the in vitro datasets used in the in silico simulation as input. In the three types of in silico features, AP features were the most reliable for determining the three Torsade de Pointes (TdP) risk standards. Among AP features, AP duration at 50% repolarization (APD(50)) was the best when individually using in silico features per in vitro dataset. In contrast, the AP repolarization velocity (dVm/dt(Max_repol)) was the best when merging all in silico features computed through three in vitro datasets.
format Online
Article
Text
id pubmed-9583152
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95831522022-10-21 Validation of in silico biomarkers for drug screening through ordinal logistic regression Jeong, Da Un Danadibrata, Rakha Zharfarizqi Marcellinus, Aroli Lim, Ki Moo Front Physiol Physiology Since the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiation, many studies have suggested various in silico features based on ionic charges, action potentials (AP), or intracellular calcium (Ca) to assess proarrhythmic risk. These in silico features are computed through electrophysiological simulations using in vitro experimental datasets as input, therefore changing with the quality of in vitro experimental data; however, research to validate the robustness of in silico features for proarrhythmic risk assessment of drugs depending on in vitro datasets has not been conducted. This study aims to verify the availability of in silico features commonly used in assessing the cardiac toxicity of drugs through an ordinal logistic regression model and three in vitro datasets measured under different experimental environments and with different purposes. We performed in silico drug simulations using the Tomek-Ohara Rudy (ToR-ORD) ventricular myocyte model and computed 12 in silico features comprising six AP features, four Ca features, and two ion charge features, which reflected the effect and characteristics of each in vitro data for CiPA 28 drugs. We then compared the classific performances of ordinal logistic regressions according to these 12 in silico features and used in vitro datasets to validate which in silico feature is the best for assessing the proarrhythmic risk of drugs at high, intermediate, and low levels. All 12 in silico features helped determine high-risky torsadogenic drugs, regardless of the in vitro datasets used in the in silico simulation as input. In the three types of in silico features, AP features were the most reliable for determining the three Torsade de Pointes (TdP) risk standards. Among AP features, AP duration at 50% repolarization (APD(50)) was the best when individually using in silico features per in vitro dataset. In contrast, the AP repolarization velocity (dVm/dt(Max_repol)) was the best when merging all in silico features computed through three in vitro datasets. Frontiers Media S.A. 2022-10-06 /pmc/articles/PMC9583152/ /pubmed/36277213 http://dx.doi.org/10.3389/fphys.2022.1009647 Text en Copyright © 2022 Jeong, Danadibrata, Marcellinus and Lim. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Physiology
Jeong, Da Un
Danadibrata, Rakha Zharfarizqi
Marcellinus, Aroli
Lim, Ki Moo
Validation of in silico biomarkers for drug screening through ordinal logistic regression
title Validation of in silico biomarkers for drug screening through ordinal logistic regression
title_full Validation of in silico biomarkers for drug screening through ordinal logistic regression
title_fullStr Validation of in silico biomarkers for drug screening through ordinal logistic regression
title_full_unstemmed Validation of in silico biomarkers for drug screening through ordinal logistic regression
title_short Validation of in silico biomarkers for drug screening through ordinal logistic regression
title_sort validation of in silico biomarkers for drug screening through ordinal logistic regression
topic Physiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583152/
https://www.ncbi.nlm.nih.gov/pubmed/36277213
http://dx.doi.org/10.3389/fphys.2022.1009647
work_keys_str_mv AT jeongdaun validationofinsilicobiomarkersfordrugscreeningthroughordinallogisticregression
AT danadibratarakhazharfarizqi validationofinsilicobiomarkersfordrugscreeningthroughordinallogisticregression
AT marcellinusaroli validationofinsilicobiomarkersfordrugscreeningthroughordinallogisticregression
AT limkimoo validationofinsilicobiomarkersfordrugscreeningthroughordinallogisticregression